GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2008

Dainippon Sumitomo Pharma Taps BioSeek to Advance R&D in Inflammation and Metabolic Diseases

  • BioSeek and Dainippon Sumitomo Pharma (DSP) signed an agreement for R&D in inflammation and metabolic diseases. BioSeek will apply its BioMAP® Systems to support compound differentiation, lead development, and drug candidate selection activities for DSP’s discovery programs.

    BioMAP Systems are a series of human primary cell-based assays designed to replicate cell and pathway interactions present in human disease biology. BioMAP profiling provides insight into human pharmacological properties of compounds, including characterization of biological drug function, on- and off-target activities, and biomarker identification.

    “The BioMAP platform represents a very compelling approach to applying human systems biology to pharmaceutical research and development,” remarks Yuichi Yokoyama, M.D., executive director at DSP. “BioMAP Systems deliver otherwise difficult-to-obtain human biological information, which will help us prioritize leads and candidates.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »